130.50
-1.14 (-0.87%)
| Previous Close | 131.64 |
| Open | 132.02 |
| Volume | 97,216 |
| Avg. Volume (3M) | 1,136,693 |
| Market Cap | 13,097,432,064 |
| Price / Earnings (TTM) | 27.94 |
| Price / Earnings (Forward) | 25.77 |
| Price / Sales | 5.60 |
| Price / Book | 5.03 |
| 52 Weeks Range | |
| Earnings Date | 4 May 2026 |
| Profit Margin | 12.68% |
| Operating Margin (TTM) | 4.14% |
| Diluted EPS (TTM) | 2.95 |
| Quarterly Revenue Growth (YOY) | 11.10% |
| Quarterly Earnings Growth (YOY) | -81.80% |
| Total Debt/Equity (MRQ) | 19.45% |
| Current Ratio (MRQ) | 3.13 |
| Operating Cash Flow (TTM) | 529.90 M |
| Levered Free Cash Flow (TTM) | 235.48 M |
| Return on Assets (TTM) | 8.75% |
| Return on Equity (TTM) | 12.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Neurocrine Biosciences, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.88 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Core |
| % Held by Insiders | 1.06% |
| % Held by Institutions | 98.86% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 204.00 (Citigroup, 56.32%) | Buy |
| Median | 176.00 (34.87%) | |
| Low | 140.00 (BMO Capital, 7.28%) | Hold |
| 140.00 (Truist Securities, 7.28%) | Buy | |
| Average | 170.73 (30.83%) | |
| Total | 10 Buy, 1 Hold | |
| Avg. Price @ Call | 125.94 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wolfe Research | 24 Feb 2026 | 160.00 (22.61%) | Buy | 130.96 |
| JP Morgan | 17 Feb 2026 | 176.00 (34.87%) | Buy | 127.76 |
| 12 Jan 2026 | 177.00 (35.63%) | Buy | 132.66 | |
| Truist Securities | 17 Feb 2026 | 140.00 (7.28%) | Buy | 127.76 |
| Wells Fargo | 13 Feb 2026 | 175.00 (34.10%) | Buy | 124.12 |
| BMO Capital | 12 Feb 2026 | 140.00 (7.28%) | Hold | 123.10 |
| Citigroup | 12 Feb 2026 | 204.00 (56.32%) | Buy | 123.10 |
| HC Wainwright & Co. | 12 Feb 2026 | 192.00 (47.13%) | Buy | 123.10 |
| Needham | 12 Feb 2026 | 185.00 (41.76%) | Buy | 123.10 |
| RBC Capital | 12 Feb 2026 | 177.00 (35.63%) | Buy | 123.10 |
| Wedbush | 12 Feb 2026 | 151.00 (15.71%) | Buy | 123.10 |
| UBS | 23 Jan 2026 | 178.00 (36.40%) | Buy | 136.18 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Jan 2026 | Announcement | Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia |
| 21 Jan 2026 | Announcement | Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results |
| 15 Jan 2026 | Announcement | Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |